Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 181.36 Million | USD 17.85 Million | 20.9% | 2022 |
The global CRM197 market size was evaluated at $181.36 million in 2022 and is slated to hit $248.19 million by the end of 2030 with a CAGR of nearly 5.81% between 2023 and 2030.
The market report is an indispensable guide on growth factors, challenges, restraints, and opportunities in the global market space. The CRM197 industry report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, PESTEL analysis, SWOT analysis, Porter’s five force analysis, and value chain analysis. Additionally, the CRM197 market report explores the investor and stakeholder space to help companies make data-driven decisions.
CRM197 is a non-toxic diphtheria toxin mutant that is used as a protein carrier for haptens and polysaccharides to make them immunogenic. Reportedly, the product is considered to be an ideal protein carrier and finds a slew of applications in approved conjugate vaccines that are used against encapsulated bacteria. Moreover, it is being assessed as a potential medicine-delivery fusion protein. In addition to this, CRM197 can also be utilized for preventing cancers having poor prognoses. It can be used in vaccines to make an individual immune to diseases such as pneumococcus, Haemophilus influenzae, and meningococcal meningitis.
Escalating demand for vaccines offering protection against chronic diseases will steer the global market trends
The massive demand for protective vaccines and the surge in the investments in biotech sector for developing new vaccines will prompt the expansion of the global CRM197 market. Growing government aid for developing conjugate vaccines will spearhead the expansion of the market across the globe. Furthermore, clinical studies have revealed that CRM197 is fit to be used for the conjugation of peptide epitopes, a vaccine approach that finds applications in streptococcal infection treatment, Alzheimer's disease treatment, and cancer therapy. This aspect will create huge demand for CRM197 in the healthcare sector, thereby driving market penetration.
A rise in spending by private firms and governments on research & development activities as well as distribution will catapult the demand for CRM197 in the medical sector. New product launches and strategic alliances will play a key role in influencing global market demand in the years ahead. For instance, in July 2023, Fina Biosolutions, LLC, a U.S-based biotech firm manufacturing cost-effective conjugate vaccines for developing countries, partnered with Scorpius BioManufacturing, a biologic contract development & manufacturing organization, for producing E.Coli expressed CRM197 conjugate vaccine protein carrier. The strategic alliance will manufacture CRM197 in bulk based on the current good manufacturing practice (CGMP) regulations of the U.S. FDA. The initiative will contribute majorly towards the global market proceeds.
Side effects such as diarrhea and restless sleep can put brakes on the global industry over 2023-2030
The use of CRM197 in diphtheria vaccines can face problems due to the presence of antibodies in humans that can hinder the effectiveness of the vaccine. This, in turn, can halt the application of the CRM197 in the diphtheria vaccine, thereby halting the expansion of the CRM197 industry surge across the globe. Moreover, gastrointestinal symptoms such as diarrhea, vomiting, and appetite loss as well as irritability and restless sleep are some of the side effects caused by the diphtheria CRM197 protein conjugate vaccine.
The rise in the use of CRM197 in chemotherapy will open new horizons of growth for the market across the globe
CRM197 has played a pivotal part in various vaccines which will help in preventing chronic infections such as pneumonia and meningitis. This, in turn, will open new growth opportunities for the global CRM197 market. Apart from this, these products can be easily prepared and it offers protection against chronic ailments in vulnerable patient population such as infants. Moreover, CRM197 finds clinical applications in chemotherapy. All these aforementioned aspects will open new dimensions of growth for the global market.
Huge raw material costs can pose a daunting task for the global industry over 2023-2030
Changing government policies pertaining to the use of various drugs for preparing vaccines along with the inaccessibility of these products can pose a huge challenge to the growth of the global CRM197 industry. Moreover, the high costs of components used for manufacturing the drug can further obstruct global industry expansion.
The global CRM197 market is sectored into type, application, and region.
In type terms, the global CRM197 market is segregated into research grade CRM197 and CGMP Grade CRM197 segments. In addition to this, the CGMP Grade CRM197 segment, which gathered nearly 60% of the global market share in 2022, is slated to record the fastest CAGR in the forecast timeline. The growth of the segment in the next couple of years can be attributed to the extensive demand for CGMP Grade CRM197 as a protein carrier in various kinds of conjugate vaccines against streptococcus pneumoniae, Neisseria meningitides, and Haemophilus influenzae b.
On the basis of the application, the CRM197 industry across the globe is sectored into meningococcal polysaccharide conjugate vaccine and pneumococcal conjugate vaccine segments. Furthermore, the pneumococcal conjugate vaccine segment, which gained a sizable share of the global industry in 2022, is expected to lead the application segment in the forecasting timespan. The segmental surge in the forecast timeframe can be subject to a rise in the use of CRM197 in preparing vaccines for pneumonia for children.
Report Attributes | Report Details |
---|---|
Report Name | CRM197 Market Report |
Market Size in 2022 | USD 181.36 Million |
Market Forecast in 2030 | USD 248.19 Million |
Growth Rate | CAGR of 5.81% |
Number of Pages | 215 |
Key Companies Covered | Xpress Biologics, Pfizer Inc., Fina Biosolutions LLC, Eubiologics, EirGenix Inc., Scarab Genomics, Beijing Kexing Biology Product, Ligand Pharmaceuticals, and CanSino Biologic. |
Segments Covered | By Type, By Application, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to account for a major share of the global market over the analysis timeline
North America, which accounted for more than 55% of the global CRM197 market share in 2022, is predicted to lead the global market over the expected timeline. The market surge in the region over the assessment timeline can be due to a rise in the number of biotech & pharmaceutical firms in countries such as the U.S. and Canada. Apart from this, the rise in research activities in the healthcare & biotech sectors will contribute majorly towards the regional market proceeds in the years ahead. In addition to this, new players are entering the biotech industry and are trying to launch new vaccines. Furthermore, the U.S. FDA is approving newly launched cost-effective vaccines for preventing chronic diseases and this has paved the way for the expansion of the market in the region.
Moreover, the CRM197 industry in the Asia-Pacific zone is set to record the fastest CAGR in the assessment timeframe. The key growth drivers of the industry in the region include a rise in the demand for vaccines for chronic ailments in children in densely populated countries & emerging economies such as India and China. Apart from this, key players in the biotech sector are setting up their vaccine manufacturing units in these countries and this will pave the way for the expansion of the industry in the region.
The global CRM197 market profiles key players such as:
By Type
By Application
FrequentlyAsked Questions
CRM197 is a non-toxic diphtheria toxin mutant that is used as a protein carrier for haptens and polysaccharides to make them immunogenic. Reportedly, the product is considered to be an ideal protein carrier and finds a slew of applications in approved conjugate vaccines that are used against encapsulated bacteria. Moreover, it is being assessed as a potential medicine-delivery fusion protein. In addition to this, CRM197 can also be utilized for preventing cancers having poor prognoses. It can be used in vaccines to make an individual immune to diseases such as pneumococcus, Haemophilus influenzae, and meningococcal meningitis.
The global CRM197 market growth is owing to a rise in spending by private firms and government on research & development activities as well as distribution.
According to a study, the global CRM197 industry size was $181.36 million in 2022 and is projected to reach $248.19 million by the end of 2030.
The global CRM197 market is anticipated to record a CAGR of nearly 5.81% from 2023 to 2030.
The Asia-Pacific CRM197 industry is set to register the highest CAGR over the forecasting timeline owing to a rise in the demand for vaccines for chronic ailments in children in densely populated countries & emerging economies such as India and China. Apart from this, key players in the biotech sector are setting up their vaccine manufacturing units in these countries and this will pave the way for the expansion of the industry in the region.
The global CRM197 market is led by players such as Xpress Biologics, Pfizer Inc., Fina Biosolutions, LLC, Eubiologics, EirGenix Inc., Scarab Genomics, Beijing Kexing Biology Product, Ligand Pharmaceuticals, and CanSino Biologic.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed